Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
St. Jude Children's Research Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Children's Oncology Group
The University of Texas Health Science Center, Houston
Ipsen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ipsen
St. Jude Children's Research Hospital
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
University of Alabama at Birmingham
Emory University
Children's Oncology Group
Mayo Clinic
Florida International University
Pediatric Brain Tumor Consortium
Ann & Robert H Lurie Children's Hospital of Chicago
Emory University
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
M.D. Anderson Cancer Center
Children's Oncology Group
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
London School of Hygiene and Tropical Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Pediatric Brain Tumor Consortium
Pediatric Brain Tumor Consortium